Kaiyu Bio completed tens of millions of yuan of round A financing for the main project preclinical development

Kaihe Bio today announced the completion of tens of millions of yuan of round A financing, by Jundudi Investment and Vosseng Capital co-investment. This round of financing will be used primarily for preclinical development of major projects. Life Capital acted as an exclusive financial advisor to assist in this round of financing.
Qiyu Biotechnology (Shanghai) Co., Ltd. ("QureBio", "QureBio"), registered in the Shanghai Free Trade Zone, is a research and development company focused on innovative large-molecule biopharmaceers, with the goal of developing new drugs for the benefit of patients in the field of difficult cancers, autoimmune and other diseases in China and the world.
The innovative platforms of kai-healing organisms include phage display technology platform, hybrid tumor antibody humanized platform, mono-domain antibody platform and antibody engineering. Among them, the hybrid tumor antibody humanization platform can overcome immune tolerance, successfully completed several multi-span membrane antigen projects, phage display platform is a synthetic human source library platform, for dual-specific antibody screening common light chain library.
Kaiyu Bio will rely on its own platform to develop a new biological drug with its own intellectual property rights, there are currently several antibody drugs in the study, two independent research and development projects have entered the process development stage, the next two years will complete the first batch of projects of preclinical research and into the clinical research stage. (Arterial mesh)